CIM24SAPP1-I-05

CIM24SAPP1-I-05 is a high-yielding, intermediate-maturing maize hybrid with white grain and drought tolerance, that is NUE and resistant to GLS, TLB, ear rots, and MSV, suitable for food use in tropical, rainfed, dry/wet mid-altitude and transition ecologies in southern Africa and similar agroecologies.    General Information   Target region Southern Africa   Adaptation/Agroecological zone 400-1800 masl   Type of product Three-way cross hybrid   Year first announced 2025         Grain Characteristics   Grain color White       Grain texture Semi- dent Grain Yield       Grain yield under optimum conditions 10.41 t/ha   Biotic Stress Performance Grain yield under managed drought 3.35 t/ha   Turcicum leaf blight (TLB) (1-9)* 4.1 Grain yield under low nitrogen 2.55 t/ha   Grey leaf spot (GLS) (1-9)* 2.9 Grian Yield on-farm (moderate stress) 5.60 t/ha   Maize Streak Virus (MSV) (1-9)* 3.9 Grain Yield on-farm (severe stress) 2.04 t/ha   Ear rots 6.9%       *Diseases are scored on a 1-9 scale, where 1 = Highly resistant; 5 = Tolerant; 9 = Highly susceptible. Agronomic Characteristics     Maturity group Intermediate       50% anthesis 65 DAP   Seed Production Characteristics   890   Single-cross female parent yield 13.2 t/ha Anthesis-silking interval 0.50 Days   Male parent yield 2.35 t/ha Plant height 227.02 cm   Nicking 1.5 Ear height 117.9 cm       Ears per plant 1.01   Comments Ear position (ratio) 0.51   Product information is based on data from CIMMYT Southern Africa 2024 Stage 4 and 2024 Stage 5 Trials. Actual performance will vary depending on a number of agronomic and environmental factors.

Abbreviations:
DAP = days after planting
GLS = Grey Leaf Spot
masl = meters above sea level
MSV= Maize Streak Virus
NUE = Nitrogen Use Efficient
TLB = Turcicum Leaf Blight Bad husk cover 7.1   Ear aspect (1-5)* 2.9   Root lodging 7.7%   Stalk lodging 2.5%   *Ear aspect is scored on 1-5 scale, where 1 = desirable and 5 = undesirable characteristics           Further Links   Full Product Announcement
(including trial results summary and site information)